Alfapump®系统与大容量腹腔穿刺术治疗难治性腹水的多中心随机对照研究
这项在七个中心开展的随机对照试验纳入60例难治性腹水患者(58例分析),比较alfapump®系统与标准大容量腹腔穿刺术。结果显示,alfapump组首次大容量腹腔穿刺的中位时间在6个月内未达到,而标准治疗组为15.0天(HR 0.13;95%CI 13.0-22.0;p<0.001),且alfapump组慢性肝病问卷评分显著改善。但alfapump组严重不良事件发生率显著更高(85.2% vs 45.2%,p=0.002),生存率两组相似。
要点
- 与标准治疗相比,alfapump显著减少难治性腹水患者对大容量腹腔穿刺的需求(HR 0.13;95%CI 13.0-22.0;p<0.001)。
- alfapump组严重不良事件发生率显著高于标准治疗组(85.2% vs 45.2%,p=0.002),但多数可治疗。
- alfapump组慢性肝病问卷评分较标准治疗组显著改善(p<0.05)。
核心结论
- alfapump系统可有效减少肝硬化难治性腹水患者对腹腔穿刺的需求并改善生活质量。
- 尽管alfapump组严重不良事件频率显著更高,但一般有限且未影响生存。
研究设计与样本
- 多中心随机对照试验,在七个中心开展,观察期六个月。
- 共60例患者随机分组,58例纳入分析(alfapump组27例,标准治疗组31例,平均年龄61.9岁,平均MELD评分11.7)。
- 亚研究纳入18例患者,评估营养、血流动力学和肾损伤生物标志物,随访三个月。
主要发现
- 与标准治疗组相比,alfapump组首次大容量腹腔穿刺的中位时间在六个月后未达到,标准治疗组为15.0天(HR 0.13;95%CI 13.0-22.0;p<0.001)。
- alfapump组慢性肝病问卷评分较标准治疗组显著改善(组间p<0.05)。
- 亚研究中,握力(p=0.044)和体重指数(p<0.001)的营养参数有所改善。
- alfapump组报告不良事件的患者比例高于标准治疗组(96.3% vs 77.4%,p=0.057),严重不良事件比例也更高(85.2% vs 45.2%,p=0.002)。
- 不良事件主要包括术后即刻急性肾损伤和因泵相关问题再次干预,多数可治疗;两组生存率相似。
临床怎么用
- 对于肝硬化难治性腹水患者,alfapump系统可减少腹腔穿刺需求并改善生活质量,但严重不良事件发生率更高,且多数可治疗、未影响生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patients with refractory ascites (RA) require repeated large volume paracenteses (LVP), which involves frequent hospital visits and is associated with a poor quality-of-life. This study assessed safety and efficacy of an automated, low-flow pump (alfapump® [AP]) compared with LVP standard of care [SoC]. METHODS: A randomized controlled trial, in seven centers, with six month patient observation was conducted. Primary outcome was time to first LVP. Secondary outcomes included paracentesis requirement, safety, health-related quality-of-life (HRQoL), and survival. Nutrition, hemodynamics, and renal injury biomarkers were assessed in a sub-study at three months. RESULTS: Sixty patients were randomized and 58 were analyzed (27 AP, 31 SoC, mean age 61.9years, mean MELD 11.7). Eighteen patients were included in the sub-study. Compared with SoC, median time to first LVP was not reached after six months in the AP group, meaning a significant reduction in LVP requirement for the AP patients (AP, median not reached; SoC, 15.0days (HR 0.13; 95%CI 13.0-22.0; p<0.001), and AP patients also showed significantly improved Chronic Liver Disease Questionnaire (CLDQ) scores compared with SoC patients (p<0.05 between treatment arms). Improvements in nutritional parameters were observed for hand-grip strength (p=0.044) and body mass index (p<0.001) in the sub-study. Compared with SoC, more AP patients reported adverse events (AEs; 96.3% vs. 77.4%, p=0.057) and serious AEs (85.2 vs. 45.2%, p=0.002). AEs consisted predominantly of acute kidney injury in the immediate post-operative period, and re-intervention for pump related issues, and were treatable in most cases. Survival was similar in AP and SoC. CONCLUSIONS: The AP system is effective for reducing the need for paracentesis and improving quality of life in cirrhotic patients with RA. Although the frequency of SAEs (and by inference hospitalizations) was significantly higher in the AP group, they were generally limited and did not impact survival. Lay summary: The alfapump® moves abdominal fluid into the bladder from where it is then removed by urination. Compared with standard treatment, the alfapump reduces the need for large volume paracentesis (manual fluid removal by needle) in patients with medically untreatable ascites. This can improve life quality for these patients. www.clinicaltrials.gov#NCT01528410.
引用
- Bureau C, Adebayo D, Chalret de Rieu M, et al. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. J Hepatol. 2017. PMID: 28645737. doi:10.1016/j.jhep.2017.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。